A systematic review and meta-analysis of the efficacy and safety of long-acting release somatostatin analogs in patients with advanced neuroendocrine neoplasms

Abstract

Background: Because the morbidity of neuroendocrine neoplasms (NENs) increases each year, clinical trials are increasingly exploring treatment options to control tumor growth. These trials have revealed that long-acting release (LAR) somatostatin analogs (SSAs) are effective therapies. The objective for this article is to perform a meta-analysis to assess the efficiency and safety of SSAs in delaying NEN progress.